Biologic drugs, including monoclonal antibodies (mAbs), are widely used to treat cancers and chronic diseases such as autoimmune and metabolic disorders. Unlike small-molecule drugs, biologics are large, structurally complex proteins that require parenteral administration due to their instability in the gastrointestinal tract.

The discovery of monoclonal antibodies (mAbs) for therapeutic and research applications has been a cornerstone of modern biotechnology. Two conventional approaches, hybridoma technology and single B cell screening, have historically driven the field, offering distinct strengths and limitations.

Discover Infliximab, the first monoclonal antibody for inflammatory diseases. Explore our catalog of antibody products for in vivo research today.

Anti-amyloid antibodies are designed to target and remove amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease. These plaques are toxic protein clusters believed to disrupt communication between neurons, leading to cell death and cognitive decline. By binding to amyloid-beta, these antibodies aim to neutralize or clear the plaques, potentially slowing disease progression.

Hybridoma technology is a common method to produce monoclonal antibodies (mAbs) and involves the fusion of antibody-producing B lymphocytes obtained from immunized mice with immortal myeloma cell lines. This fusion gives rise to hybridoma cell lines which are cultivated to produce mAbs targeted against a specific antigen.

For more than 30 years, antibody drug development has transformed the landscape of immunotherapy, treating various diseases from cancer to autoimmune diseases. The use of therapeutic monoclonal antibodies (mAbs) began after the groundbreaking development of the hybridoma technique by Kohler and Milstein in 1975, with further development into humanization approaches over the next decade.

T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is an immune receptor that plays a key role in suppressing T-cell activation and proliferation. As a newly identified checkpoint, it is highly expressed on various immune cells, including CD4+ and CD8+ T cells, NK cells.

Explore antibody therapeutics, from monoclonal antibodies to innovative formats like ADCs & bispecifics, revolutionizing treatment for cancer, autoimmune, and infectious diseases.

Discover monoclonal antibodies (mAbs), their role in treating cancer, autoimmune, and infectious diseases, and how they revolutionize therapy & research.

Discover the applications of antibodies in research, diagnostics, & therapeutics. Learn the differences between polyclonal, monoclonal, & recombinant antibodies.

In August, the US FDA approved Galderma’s Nemluvio (nemolizumab) for adult patients living with prurigo nodularis (PN). Nemluvio is the first approved monoclonal antibody specifically inhibiting the signaling of IL-31, a neuroimmune cytokine that drives multiple disease mechanisms in (PN). Prurigo nodularis is a chronic skin condition that affects approximately 181,000 patients in the United States

Hepatitis B virus (HBV) infection is a major global health issue, driven by high levels of immunosuppressive viral antigens, the host immune system's failure to effectively control the virus, and the immunosuppressive environment of the liver. Existing therapies have limited effectiveness in eliminating the hepatitis B surface antigen (HBsAg).

The approval of Eli Lilly’s Kisunla (donanemab-azbt), a humanized IgG1 monoclonal antibody, is just one of the major advancements in the treatment of Alzheimer's disease (AD)! This drug is now available in the US for adults with early symptomatic AD, including those with mild cognitive impairment (MCI) and mild dementia stage of AD with amyloid pathology.

Discover how antibody-antibiotic conjugates (AACs) target resistant bacteria, combining mAb precision & antibiotic power to tackle infections like MRSA effectively.

Ozempic, a brand name for the drug semaglutide, was originally developed to manage type 2 diabetes by improving blood sugar control. As a GLP-1 receptor agonist, it mimics a hormone that regulates glucose metabolism and appetite. Beyond its success in diabetes treatment, Ozempic has garnered signifi